Germany Medical Cannabis Market, by Derivative

Growth Outlook

• The Germany Medical Cannabis Market, by Derivative market is on a steady long-term growth path. Segment value stands at roughly USD 3007 Mn in 2026 and is projected to reach USD 3787 Mn by 2027 — a gain of about 26% over the forecast period, translating to a CAGR in the double digits.
• What the regional split looks like (2026): Cannabidiol leads, holding roughly 72% of segment value — the single largest regional share. Tetrahydrocannabinol is the second-largest contributor.
• By 2027, Cannabidiol alone is expected to reach USD 2731 Mn, with Tetrahydrocannabinol at USD 1056 Mn.

Market Dynamics

Germany has emerged as a key player in the global medical cannabis market, with a growing demand for cannabis-based products and treatments. While the market is still in its early stages, Germany's progressive stance towards cannabis and its potential medical benefits has led to an increase in demand for various cannabis derivatives.

One of the key derivatives in demand in Germany is cannabidiol (CBD). CBD is non-psychoactive and has been found to have potential medical benefits, including reducing anxiety and relieving pain. In Germany, CBD products can be legally sold and purchased as long as they contain less than 0.2% of tetrahydrocannabinol (THC), the psychoactive component of cannabis.

CBD oils, tinctures, and capsules are some of the most popular CBD products in Germany. They are easily accessible, with many pharmacies and drugstores stocking them. CBD can also be found in various cosmetics and skincare products, catering to the growing demand for natural and organic beauty products. Additionally, CBD-infused foods and beverages, such as chocolates, gummies, and teas, have also gained popularity in the German market.

Another highly sought-after derivative in the German medical cannabis market is delta-9-tetrahydrocannabinol (THC). Unlike CBD, THC is psychoactive and has recreational effects. However, it also has potential medical benefits, such as pain relief and reducing nausea and vomiting. In Germany, THC-based products can only be obtained with a prescription and are mostly used for managing symptoms of chronic conditions, such as multiple sclerosis and cancer.

In recent years, Germany has also seen a rise in demand for medical cannabis extracts. These extracts, such as tinctures, sprays, and concentrates, are made from the whole cannabis plant and contain a full spectrum of cannabinoids. They are becoming increasingly popular as they offer a more potent form of cannabis and can be used for various medical purposes.

In addition to these derivatives, Germany's medical cannabis market has also seen an increase in demand for cannabis-based pharmaceuticals. These products, such as Sativex and Epidyolex, are approved by the German Federal Institute for Drugs and Medical Devices and can only be obtained with a prescription. They are used to treat specific medical conditions, including symptoms of multiple sclerosis and epilepsy.

In conclusion, the demand for various cannabis derivatives is rapidly growing in Germany's medical cannabis market. This demand is driven by the increasing awareness and acceptance of cannabis-based treatments and the country's regulatory framework allowing for the use of these derivatives for medical purposes. As the market continues to evolve, we can expect to see even more diverse and innovative cannabis-based products and treatments in the German market.